An Overview on Drug Coated Balloon

Abstract

Drug-eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by reducing restenosis and target vessel revascularization. However, permanent metallic scaffolds are associated with vascular inflammation, hypersensitivity, and late complications such as neo-atherosclerosis and stent thrombosis. Drug-coated balloons (DCB) represent an attractive alternative by delivering antiproliferative drugs directly to the vessel wall without leaving an implant behind. This strategy provides potential advantages including reduced metal burden, restoration of vasomotor function, and avoidance of long-term polymer-related complications.